No Data
No Data
Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29
Lake Street Maintains Elutia(ELUT.US) With Buy Rating, Maintains Target Price $10
Elutia Initiates EluPro Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Elutia Unaffected by Global Tariffs Due to US-Based Operations
Express News | Elutia Inc - Roswell Facility Experiences No Delays or Cost Increases From Tariffs